Sun Pharmaceutical Industries Limited

18%

ACS data for 12 months ended Dec 2024 A diversified revenue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others

14%

diversified revenue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others 5% US Formulations 32% © Sun Pharmace

Rs 478

enue base Emerging Markets Formulations 18% Rest of World (RoW)# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others 5% US Formulations 32% © Sun Pharmaceutical Industries Li

31%

Formulations 18% Rest of World (RoW)# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others 5% US Formulations 32% © Sun Pharmaceutical Industries Limited. All Rights Reserved

rs 5

8% Rest of World (RoW)# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others 5% US Formulations 32% © Sun Pharmaceutical Industries Limited. All Rights Reserved. 5 # Include

32%

# Formulations 14% FY24 Sales Rs 478 Bn India Formulations 31% API & Others 5% US Formulations 32% © Sun Pharmaceutical Industries Limited. All Rights Reserved. 5 # Includes Western Europe, Cana

12%

43 Sales CAGR 18% 130 101 71 63 19 EBITDA CAGR 14% 57 39 18 Adjusted Net Profit CAGR 12% FY09 FY14 FY19 FY24 FY09 FY14 FY19 FY24 FY09 FY14 FY19 FY24 121 99 42 40 22 22 Operating

13%

Y19 FY24 121 99 42 40 22 22 Operating Cash Flow CAGR 12% 31 16 -10 Free Cash Flow CAGR 13% 24 16 8 Adjusted EPS (Rs/Share) CAGR 12% FY09 FY14 FY19 FY24 FY09 FY14 FY19 FY24 FY09 FY1

73.9%

Strong profitability and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.9% 73.1% 77.7% 75.4% 26.9% 26.9% 26.5% 17.8% 20.0% 20.0% 21.1% 25.3% FY21 FY22 FY23 FY2

73.1%

profitability and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.9% 73.1% 77.7% 75.4% 26.9% 26.9% 26.5% 17.8% 20.0% 20.0% 21.1% 25.3% FY21 FY22 FY23 FY24 FY21

77.7%

bility and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.9% 73.1% 77.7% 75.4% 26.9% 26.9% 26.5% 17.8% 20.0% 20.0% 21.1% 25.3% FY21 FY22 FY23 FY24 FY21 FY22

75.4%

and return ratios Gross Margin # EBITDA Margin Adjusted Net Profit Margin 73.9% 73.1% 77.7% 75.4% 26.9% 26.9% 26.5% 17.8% 20.0% 20.0% 21.1% 25.3% FY21 FY22 FY23 FY24 FY21 FY22 FY23

Source

3

Note

1

Net Profit Adjustment

1

Note

(1) As of Feb, 17 2025 using spot exchange rate of INR /USD = 86.70 # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets. * Source: IQVIA data for 12 months ended Dec 2024 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 10 Driving sustainable long term growth • Achieve critical mass in key markets • Embed sustainability practices in business • Actionable targets on sustainability Sustainable growth t s o C • Optimize operational costs • Leverage benefits of vertically integrated operations i p h s r e d a e l i n v e s t m e n t s p r o f i t a b i l i t y & l B a a n c e Business development • Increase contribution of specialty and complex products • Direct future investments towards differentiated products • Use acquisitions to bridge gaps while yielding target ROI • Focus on access to novel products, technology or market presence © Sun Pharmaceutical Industries Limited. All Rights Reserved. 11 ESG Performance - FY 2023-24 Environm

Source

1, 2 & 4 Sun Press Release 3 Levulan website © Sun Pharmaceutical Industries Limited. All Rights Reserved. 15 Global Specialty portfolio Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. • ODOMZO was shown to shrink laBCC in almost 6 out of 10 patients (56%) in a clinical study. laBCC Patients were treated with ODOMZO® and followed for at least 18 months5 • Currently marketed in US, Canada, Germany, France, Denmark, Switzerland, Spain, Italy, Australia and Israel To increase tear production in patients with keratoconjunctivitis sicca (dry eye) • Phase 3 confirmatory study observed clinically and statistically significant improvements in tear production and ocular surface integrity in patients6 • Current Markets: US, Canada and India • Out-licensed to CMS for Greater China in June 2019 Treatment of postoperative inflammation and preventio

Source

5 Product Label 6 Sun Press Release 7 & 8 Product website 16 Global Specialty portfolio In combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). • YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone9 • Current Markets: US First and only product approved in the US for treating seizures in neonatal patients • NEOLEV2 study compared phenobarbital to levetiracetam in the first-line treatment of neonatal seizures. 24 hours following the administration, 73% vs. 25% were seizure-free in the respective groups10 • Current Markets: US For therapeutic solutions for long-term care (LTC) patients • Products using sprinkle technology for patients who have difficulty swallowing • Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro-psychiatry) • Current Markets: US All brand names

Source

9 & 10 Sun Press Release © Sun Pharmaceutical Industries Limited. All Rights Reserved. 17 Global Specialty pipeline Candidate Mechanism of action Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Leqselvi JAK Inhibitor severe alopecia areata Nidlegy™ Immunocytokines melanoma & non- melanoma skin cancers Ilumya IL-23 Antagonist psoriatic arthritis Fibromun Innovative anti-cancer immunotherapy soft tissue sarcoma glioblastoma MM-II Liposomal intra-articular lubrication pain in osteoarthritis SCD-044 Selective SIPR1 Agonist atopic dermatitis psoriasis GL0034 GLP-1R Agonist obesity All candidates for global markets except Nidlegy™ where Sun is commercial partner for Europe, Australia & New Zealand. Nidlegy™ is a trademark of Philogen. Creating Lasting Value - Investor Presentation 18 Global Specialty Sales Specialty Sales (USD mn) 429 485 674 871 1,039 18.0 16.2 13.1 10.8 9.4 FY20 FY21 FY22 FY23 FY24 Specialty Branded Sales Specialty Sales (%) of Total Sales • US is the major con

Net Profit Adjustment

# Q3FY24 - Adjusted for Rs 698 Mn related to the impact of Lipitor West Virginia settlement 9mFY24 - Adjusted for Rs 3.9 Bn related to (i) Impairment of intangible under development of Ache Labs = Rs. 1.5 Bn (ii) Nigeria Forex loss =Rs 1.2 Bn (iii) Alchemee restructuring cost =Rs 507 Mn (iv) Impact of Lipitor West Virginia settlement =Rs 698 Mn Q3FY25 - Adjusted for Rs 3.2 Bn related to the impact of Opioid settlement 9mFY25 - Adjusted for Rs 3.2 Bn related to the impact of Opioid settlement © Sun Pharmaceutical Industries Limited. All Rights Reserved. 52 Sales split Q3 FY25 Q3 FY25 Q3 FY24 CHANGE 9m FY25 9m FY24 CHANGE ( All Figures in Rs mn ) Formulation India US Emerging Markets ROW # ÀPI Others 43,004 40,030 23,384 21,840 37,785 39,736 20,946 17,797 Sub-total 128,258 116,264 5,678 434 4,661 644 13.8% 0.7% 11.6% 22.7% 10.3% 21.8% -32.7% 127,100 122,199 71,599 54,286 111,814 113,948 65,847 50,838 375,184 342,447 15,962 1,111 15,029 1,975 13.7% 7.2% 8.7% 6.8% 9.6% 6.2% -43.8% Gross Sa